Here’s why I’ll be watching the Medibank results like a hawk

ASX earnings season is now in full swing on the Australian share market. We’ve already heard from some big names so far, including Commonwealth Bank of Australia (ASX: CBA), CSL Ltd (ASX: CSL), Telstra Group Ltd (ASX: TLS) and Wesfarmers Ltd (ASX: WES). Next week, Medibank Private Ltd (ASX: MPL) will join them

Yes, Medibank is scheduled to drop its latest earnings, covering the six months to 31 December 2023, next Thursday, 22 February.  It’s a report I’ll be watching like a hawk.

I am interested in all of the financials the company is set to give investors a look at. Last year, my Fool colleague Tristan covered how the insurer expected to “achieve total resident policyholder growth in FY24 of between 1.5% to 2%”. It will be interesting to get a report card on how that’s going.

I’m also keen to see how Medibank’s investment portfolio is faring. After all, higher interest rates have boosted the company’s investment returns in the past.

But I’ll be paying special attention to what Medibank has to say about its next dividend.

Why I’ll be watching the next Medibank dividend

I’ve long regarded Medibank as a leading candidate in the ASX healthcare space for dividend investors. It has something that most ASX shares don’t. That’s explicit support from the Australian government.

There are many government policies that herd customers towards Medibank and its private health insurance offerings. The Medicare surcharge, lifetime health cover loadings, private health insurance rebates… not too many other ASX shares benefit from this kind of customer encouragement.

This has helped shape Medibank into a reliable dividend payer. As such, it’s the dividend announcement from Medibank that I’ll be paying the closest attention to next week.

In 2023, Medibank showered investors with its largest dividends since the company was privatised in 2014. Shareholders enjoyed a March interim dividend worth 6.3 cents per share, and a final dividend in October of 8.3 cents per share. Both payments came fully franked. And both payments were increases over 2022’s interim and final dividends of 6.2 cents and 7.3 cents per share, respectively.

These dividend payments have resulted in Medibank shares offering a generous fully-franked dividend yield of 3.86% at current pricing. If Medibank announces an even higher dividend next week, my belief that this company is a fantastic income stock for dividend investors will only solidify.

The post Here’s why I’ll be watching the Medibank results like a hawk appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Beyond ASX 200 bank shares: 3 insurance plays with nice dividends
• I’d buy these two resilient ASX dividend shares for big income
• Want a large and growing dividend? Medibank shares might be the answer
• The 3 best ASX dividend shares for 2024
• Top ASX shares to buy in 2024 instead of investing in a term deposit

Motley Fool contributor Sebastian Bowen has positions in CSL, Telstra Group and Wesfarmers. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Wesfarmers. The Motley Fool Australia has positions in and has recommended Telstra Group and Wesfarmers. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/3ZHmEqw